We are very proud to announce Ciências ULisboa spin-off R-nuucell was selected, amongst other 7 projects, for the Fast Track Validation Programme from EP PerMed – European Partnership for Personalised Medicine. (Congratulations R-nuucell!)
This is an initiative designed to accelerate the development, validation, and adoption of innovative personalised medicine (PM) solutions across Europe.
Personalised medicine is the future of medicine, in which each patient receives a specific therapeutic in a given time, resulting in better results for patients and a complete transformation of the healthcare system.
The focus of the Programme is to support start-ups and their innovations, for them to achieve at least one Technology Readiness Level (TRL). It offers 80k per project, supporting 6 months of validation studies.
About R-nuucell
A biotechnology company focused on the discovery and development of innovative chemotherapeutics to treat metastatic cancers.
Their mission is to develop innovative chemotherapeutics to treat metastatic cancers. Cancer is the second leading cause of death globally: 10 million deaths in 2020. Metastases are responsible for more than 90% of cancer deaths in resistant cancers. R-nuucell is developing innovative metallodrugs with potential to treat metastases and to overcome several forms of cancer multidrug resistance.
The treatment of metastatic and resistant cancers is an unmet medical need that R-nuucell wants to address.
DCI Ciências ULisboa
